Key points are not available for this paper at this time.
// Alejandra M. Petrilli 1 , Jeanine Garcia 1 , Marga Bott 1 , Stephani Klingeman Plati 1 , Christine T. Dinh 2 , Olena R. Bracho 2 , Denise Yan 2 , Bing Zou 2 , Rahul Mittal 2 , Fred F. Telischi 2 , Xue-Zhong Liu 2 , Long-Sheng Chang 3 , D. Bradley Welling 3, 4 , Alicja J. Copik 1 and Cristina Fernández-Valle 1 1 Burnett School of Biomedical Sciences, College of Medicine, University of Central Florida, Lake Nona-Orlando, FL 32827, USA 2 University of Miami Miller School of Medicine, Department of Otolaryngology, Miami, FL 33136, USA 3 Center for Childhood Cancer and Blood Diseases, The Research Institute at Nationwide Children’s Hospital and Department of Pediatrics, The Ohio State University College of Medicine, Columbus, OH 43205, USA 4 Current Affiliation: Department of Otolaryngology, Massachusetts Eye and Ear Infirmary, Massachusetts General Hospital and Harvard University, Boston, MA 02114, USA Correspondence to: Cristina Fernández-Valle, email: cfv@ucf.edu Keywords: neurofibromatosis type 2, schwannoma, PDGFR, SRC, STAT3 Received: August 17, 2016 Accepted: February 20, 2017 Published: March 06, 2017 ABSTRACT Neurofibromatosis type 2 (NF2) is a genetic syndrome that predisposes individuals to multiple benign tumors of the central and peripheral nervous systems, including vestibular schwannomas. Currently, there are no FDA approved drug therapies for NF2. Loss of function of merlin encoded by the NF2 tumor suppressor gene leads to activation of multiple mitogenic signaling cascades, including platelet-derived growth factor receptor (PDGFR) and SRC in Schwann cells. The goal of this study was to determine whether ponatinib, an FDA-approved ABL/SRC inhibitor, reduced proliferation and/or survival of merlin-deficient human Schwann cells (HSC). Merlin-deficient HSC had higher levels of phosphorylated PDGFRα/β, and SRC than merlin-expressing HSC. A similar phosphorylation pattern was observed in phospho-protein arrays of human vestibular schwannoma samples compared to normal HSC. Ponatinib reduced merlin-deficient HSC viability in a dose-dependent manner by decreasing phosphorylation of PDGFRα/β, AKT, p70S6K, MEK1/2, ERK1/2 and STAT3. These changes were associated with decreased cyclin D1 and increased p27 Kip1 levels, leading to a G 1 cell-cycle arrest as assessed by Western blotting and flow cytometry. Ponatinib did not modulate ABL, SRC, focal adhesion kinase (FAK), or paxillin phosphorylation levels. These results suggest that ponatinib is a potential therapeutic agent for NF2-associated schwannomas and warrants further in vivo investigation.
Petrilli et al. (Mon,) studied this question.